Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Catalyst Pharmaceuticals, Inc.

SG&A Cost Efficiency: Bristol-Myers Squibb vs. Catalyst Pharmaceuticals

__timestampBristol-Myers Squibb CompanyCatalyst Pharmaceuticals, Inc.
Wednesday, January 1, 201456990000004473654
Thursday, January 1, 201550010000008597010
Friday, January 1, 201650020000007910260
Sunday, January 1, 201748490000007304399
Monday, January 1, 2018455100000015875961
Tuesday, January 1, 2019487100000036881187
Wednesday, January 1, 2020766100000044233754
Friday, January 1, 2021769000000049628000
Saturday, January 1, 2022781400000058183000
Sunday, January 1, 20237772000000133710000
Monday, January 1, 20248414000000
Loading chart...

Unleashing insights

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Bristol-Myers Squibb Company and Catalyst Pharmaceuticals, Inc. have showcased contrasting strategies in this domain.

Bristol-Myers Squibb, a giant in the industry, has consistently maintained high SG&A expenses, peaking at approximately $7.8 billion in 2022. This reflects their expansive operations and robust marketing strategies. However, their SG&A costs have grown by about 36% since 2014, indicating a potential area for optimization.

In contrast, Catalyst Pharmaceuticals, a smaller player, has demonstrated remarkable efficiency. Their SG&A expenses, though increasing, have remained under $134 million in 2023, a fraction of Bristol-Myers Squibb's costs. This suggests a leaner operational model, with a focus on cost-effectiveness.

As the pharmaceutical industry evolves, the ability to optimize SG&A costs will remain a key differentiator for success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025